Abstract: The present application relates to a method of treating a subject having a condition mediated by a deficiency in myelin. This method involves selecting a subject having a condition mediated by a deficiency in myelin and expressing a transcription factor 7-like 2 (TCF7L2) protein in the selected subject under conditions effective to treat the condition. Also disclosed is a method of increasing oligodendrocyte production from glial progenitor cells. This method involves providing a population of glial progenitor cells and expressing a TCF7L2 protein in the provided population of glial progenitor cells under conditions effective to increase oligodendrocyte production compared to oligodendrocyte production absent said administering. Also disclosed is a genetic construct suitable, inter alia, for carrying out these methods.

Abstract: A method, system and devices to selectively control modal vibrations in an elastic panel with a number of force actuators distributed throughout the surface of the elastic panel to excite/depress the response of one or more vibrational resonant modes included in a prescribed subset. The force actuators are disposed such that prescribed modal excitation/depression may be realized when the actuators are driven by a common source signal.

Abstract: Additive manufacturing systems and methods utilizing an optical light valve configured to spatially modulate the intensity of a laser beam, in conjunction with a writing and erasing sub-system configured to repeatedly write and erase patterns in the optical light valve to repeatedly vary the spatial modulation of the laser beam. In some implementations, the systems and methods may also employ additional laser beams or other energy sources that are not spatially modulated by the optical light valve. In some implementations, the systems and methods may employ additional laser beams or other energy sources configured to reduce surface roughness of the powder or other material being used for additive manufacturing.

Abstract: A dual-modulated QR code (DMQR code) is in the format of a conventional QR code but uses elongated markers instead of black squares in the code modules. The positions of the markers within the DMQR code represent a nonconfidential primary message, and the orientations of the markers within the modules of the DMQR code represent a confidential secondary message.

Abstract: Systems and methods of driving plate loudspeakers with different parameters based on frequency region in a way similar to typical cone driver crossover networks are described. These systems and methods may be implemented using arrays of independently controlled drivers which allow a designer to emphasize or de-emphasize certain modes in certain frequency bands. Tuning the characteristics of the plate's motion can also affect the acoustical properties in a larger space rather than just at a single location. The systems and methods described herein can grant a designer a degree of control over the characteristics and performance of the plate.

Abstract: The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.

Abstract: The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K+) channel activator at a dosage effective to restore normal brain interstitial glial K+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.

Abstract: A method for modifying a refractive property of ocular tissue in an eye by creating at least one optically-modified gradient index (GRIN) layer in the corneal stroma and/or the crystalline by continuously scanning a continuous stream of laser pulses having a focal volume from a laser having a known average power along a continuous line having a smoothly changing refractive index within the tissue, and varying either or both of the scan speed and the laser average power during the scan. The method may further involve determining a desired vision correction adjustment, and determining a position, number, and design parameters of gradient index (GRIN) layers to be created within the ocular tissue to provide the desired vision correction.

Abstract: The present invention relates to enhancing mechanical properties of tissue such as collagenous or collagen-containing or elastin-containing tissue (e.g., tendons, ligaments, and cartilage) and treating related musculoskeletal and non-musculoskeletal conditions or injuries.

Abstract: a) A Gabor domain optical coherence microscopy (GD-OCM) system providing high resolution of structural and motion imaging of objects such as tissues is combined with the use of reverberant shear wave fields (RevSW) or longitudinal shear waves (LSW) and two novel mechanical excitation sources: a coaxial coverslip excitation (CCE) and a multiple pronged excitation (MPE) sources providing structured and controlled mechanical excitation in tissues and leading to accurate derivation of elastographic properties. Alternatively, general optical computed tomography (OCT) is combined with RevSW or LWC in the object to derive elastographic properties. The embodiments include (a) GD-OCM with RevSW; (b) GD-OCM with LSW; (c) General OCT with RevSW; and General OCT with LSW.

Abstract: Photonic devices and methods for operation thereof are disclosed. A photonic device may include a laser configured to generate light. The photonic device may also include a weak value device having a ring resonator. The weak value device may receive the light from the laser and modify the light using the ring resonator to form return light. The photonic device may further include a stabilizing structure configured to generate a tuning signal based on the return light and control one or both of the laser or the ring resonator using the tuning signal to lock a frequency of the laser to a resonance frequency of the ring resonator.

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

Abstract: A see-through reflective optical device includes: a reflective metasurface configured for a targeted design optical wavelength, wherein the reflective metasurface comprises a sub-wavelength periodic arrangement of meta-atoms formed by patterned isolated gap surface plasmon (GSP) resonators, where the patterned isolated GSP resonators comprise a patterned optically thin metal layer for the design wavelength, an optically thick metal layer for the design wavelength, and an insulator layer between the patterned optically thin metal layer and the optically thick metal layer; and an array of apertures of random positions and diameters greater than the targeted design wavelength formed through the reflective metasurface providing a designed percentage of light transparency through the reflective metasurface. The reflective metasurface of the see-through reflective optical device may comprise, e.g.

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.

Abstract: A transducer transmits into the bone a first plurality of excitation pulses at a plurality of frequencies and measures a plurality of echoes corresponding to the plurality of excitation pulses. An ultrasound machine calculates a plurality of energies each corresponding to a respective one of the plurality of echoes and identifies a lowest echo corresponding to a lowest of the plurality of energies. The ultrasound machine matches the lowest echo to a corresponding one of the first plurality of excitation pulses, the corresponding one of the first plurality of excitation pulses having a chosen frequency. The ultrasound machine generates an acoustic impulse response by deconvolving the corresponding one of the first plurality of excitation pulses with the lowest echo, and generates an updated sensing matrix by convolving the initial sensing matrix with the acoustic impulse response. Subsequent ultrasounds use the updated sensing matrix.

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

Abstract: This patent document discloses novel compounds as inhibitors of the activity of the histone H3K27 demethylase JMJD3. Also disclosed are the use of the compounds and compositions thereof for the treatment of diseases and conditions mediated by JMJD3, in particular cancer, inflammation and autoimmune diseases.

Abstract: The present invention relates to derivatives of the sesquiterpene lactone micheliolide, methods and compositions for their preparation, and methods for using the micheliolide derivatives in pharmaceutical compositions as anticancer and anti-inflammatory agents. The invention also relates to methods for producing micheliolide derivatives modified at positions C2 and C14. The invention also relates to methods for producing parthenolide derivatives modified at positions C2 and C14 in conjunction with modifications at position C13, via chemoenzymatic methods. The invention further relates to methods for using parthenolide derivatives for treating cancer and inflammatory diseases.

Abstract: A near eye display assembly includes (a) frame; (b) a combiner operably connected to the frame as a first reflective surface positionable in front of an eye of a user of the display assembly; (c) a secondary mirror operably connected to the frame as a second reflective surface positionable proximate a side of the nose adjacent to the eye of a user of the display assembly; (d) an image source operably connected to the frame and optically coupled to the secondary mirror along an optical path; and (e) an optical fold element between the image source and the secondary mirror in the optical path, and positionable proximate the temple adjacent to the eye of a user of the display assembly; wherein an intermediate image is formed in the optical path between the image source and the secondary mirror, wherein the combiner and the secondary mirror are in an off-axis folded geometry which directs images from the optical fold element to an eyebox of the near eye display assembly, and at least one of the combiner and the s

Abstract: A method of controlling a trajectory of a perpendicular magnetization switching of a ferromagnetic layer using spin-orbit torques in the absence of any external magnetic field includes: injecting a charge current Je through a heavy-metal thin film disposed adjacent to a ferromagnetic layer to produce spin torques which drive a magnetization M out of an equilibrium state towards an in-plane of a nanomagnet; turning the charge current Je off after te seconds, where an effective field experienced by the magnetization of the ferromagnetic layer Heff is significantly dominated by and in-plane anisotropy Hkx, and where M passes a hard axis by precessing around the Heff; and passing the hard axis, where Heff is dominated by a perpendicular-to-the-plane anisotropy Hkz, and where M is pulled towards the new equilibrium state by precessing and damping around Heff, completing a magnetization switching.